Mangoceuticals, Inc. - MGRX STOCK NEWS

MangoRx, a men's health and wellness company, has announced the development of oral formulations of Semaglutide and Tirzepatide, branded as 'Slim' and 'Trim.' These drugs, traditionally available as injectables, are designed to aid in weight management. Clinical trials have shown impressive weight loss results, with Semaglutide yielding a 15.2% weight loss and Tirzepatide 15.7% over one year. The GLP-1 receptor agonists' market is projected to reach $164 billion by 2032. MangoRx's oral versions are expected to capture a significant market share due to patient preference for oral medications. The products will be available on MangoRx's telemedicine platform by Q3 2024, priced at $299/month for 'Slim' and $399/month for 'Trim.'

MangoRx (NASDAQ: MGRX) reported a 108% revenue growth in Q1 2024, increasing from $100,000 to $214,000 compared to Q1 2023. This growth is driven by strategic advances in customer acquisition, including the launch of a direct-to-clinic sales division. This allows medical professionals to prescribe MangoRx products directly, reducing customer acquisition costs. The company also acquired a global patent portfolio valued at $35 million for $20 million, aiming to launch non-pharmaceutical products starting with clinical trials in Q3 2024. MangoRx continues to expand its men's health and wellness product line, leveraging a unique telemedicine platform for seamless patient experience.

Mangoceuticals, Inc. (NASDAQ: MGRX) received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement and conditional approval of compliance with Nasdaq’s minimum stockholders’ equity requirement. The company must reach a bid price of $1.00 per share for ten consecutive days to avoid delisting. Additionally, the 2024 Annual Meeting of Stockholders is scheduled for June 17, 2024.

Mangoceuticals, Inc. (NASDAQ: MGRX) acquires a global patent portfolio for a preventive oral solution to combat various infections, expanding into the nutraceutical product space. The patented solution includes unique ingredients like GALALCOOL®️, zinc protoporphyrin IX, and select tannins, offering users a defense against oral and respiratory infections. The acquisition aims to tap into the growing demand for high-quality oral health products, driven by a $25.71 billion market opportunity by 2030. MangoRx plans to commercialize the technology through direct-to-consumer online platforms and retail locations, aligning with its mission to enhance well-being through innovative health solutions.

Mangoceuticals, Inc. (NASDAQ: MGRX) announces a technical agreement with Emifarma S.A. de C.V for the development and testing of Mango ED products for the Mexican and Latin American markets. This marks a significant step towards obtaining certification from COFEPRIS, opening doors for expansion into multiple markets.

Mangoceuticals, Inc. (NASDAQ: MGRX) introduces 'PRIME' by MangoRx, an FDA-approved oral testosterone replacement therapy treatment, targeting men with low testosterone. The company aims to tap into a significant market of men seeking alternative TRT options, leveraging its telehealth platform.

Mangoceuticals, Inc. (NASDAQ: MGRX) launches a direct-to-clinics sales division, allowing doctors to prescribe MangoRx products from their offices. The company aims to increase recurring revenues and reduce customer acquisition costs by deploying a sales force to penetrate men’s health and wellness clinics across the US. The newly developed clinic prescribing system enables practitioners to prescribe MangoRx products, including the recently launched 'PRIME', by MangoRx, powered by Kyzatrex®️.

Mangoceuticals, Inc. (Nasdaq: MGRX) offers San Francisco players and coaches a free one-year supply of its 'Mango' erectile dysfunction product following a Big Game loss. Fans can also get 3 free Mango pills with a special discount code 'SB58'. The product contains active ingredients from Cialis and Viagra, compounded with Oxytocin and L-Arginine in a Mango-flavored rapid dissolve tablet.

Mangoceuticals, Inc. (Nasdaq: MGRX) announces a promotion offering the losing team of the Big Game a free one-year supply of its Mango ED products. Fans can also get a special discount code equal to the game's point difference. The company's uniquely formulated Mango ED products are designed to help men tackle performance issues in the bedroom. MangoRx will also be the marquee sponsor for several Barstool Sports' week-long programming surrounding the Big Game in Las Vegas.